Clinical Trial: Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07008963) titled 'Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant' on May 05.

Brief Summary: A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed

Study Start Date: June 16

Study Type: OBSERVATIONAL

Condition: Metastatic Breast Cancer

Intervention: OTHER: non-interventional

This is a non-interventional, observational study

Recruitment Status: NOT_YET_RECRUITING

Sponsor: AstraZeneca

Disclaimer: Curated by HT Syndication....